glp 1 receptor agonist heart failure Cardiovascular Effects of Glucagon-Like Peptide-1 Agonists Glucagon-like peptide 1(GLP-1) receptor agonists
Description
How Payer Friction and Patient Drop-Off Undermine Obesity GLP-1 Uptake The GLP-1 market is experiencing unprecedented demand, yet despite its clinical promise for obesity, diabetes, and other conditions, patient behavior and friction throughout the treatment journey continue to erode its commercial potential
C.FinkelsteinJ.et al
We spoke with Wolver about the science behind these drugs and how they may affect you
Similar content being viewed by others Introduction A progressive decline in skeletal muscle mass and strength, or sarcopenia, is increasingly recognized as a significant comorbidity in patients with type 2 diabetes mellitus (T2D) and obesity [1, 2]
doi:10.1210/er.2018-00168 173
Going forward, continued innovation in manufacturing (e.g
